1. Home
  2. PRQR vs TKNO Comparison

PRQR vs TKNO Comparison

Compare PRQR & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProQR Therapeutics N.V.

PRQR

ProQR Therapeutics N.V.

N/A

Current Price

$1.84

Market Cap

262.5M

Sector

Health Care

ML Signal

N/A

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

N/A

Current Price

$6.90

Market Cap

268.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRQR
TKNO
Founded
2012
1996
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
262.5M
268.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
PRQR
TKNO
Price
$1.84
$6.90
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$7.25
N/A
AVG Volume (30 Days)
887.4K
183.7K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.86
EPS
N/A
N/A
Revenue
N/A
$40,520,000.00
Revenue This Year
N/A
$8.27
Revenue Next Year
$13.92
$13.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.35
52 Week Low
$1.33
$1.91
52 Week High
$3.10
$7.84

Technical Indicators

Market Signals
Indicator
PRQR
TKNO
Relative Strength Index (RSI) 37.87 50.49
Support Level $1.37 $4.87
Resistance Level $1.99 $7.66
Average True Range (ATR) 0.11 0.37
MACD -0.06 -0.12
Stochastic Oscillator 7.92 37.40

Price Performance

Historical Comparison
PRQR
TKNO

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

Share on Social Networks: